Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00001165 · ClinicalTrials.gov registry record · Phase 2
Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas
A Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- Completed
- Registry status
- Phase 2
- Development phase
- 999
- Enrollment target
NCT00001165: Completed Phase 2 study, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
NCT00001165 is a Phase 2 study that has completed, run by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). The registered enrollment target is 999 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (651% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00001165, a Phase 2 study, has completed, sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 999 participants
- Enrollment target
Study Summary
Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors. Prior to the use of drugs to cure the ulcers, patients typically died due to severe ulcers. Because of such effective drugs to treat the ulcers it is more common to see patients dying due to the pancreatic tumors. The study will observe patients suffering from Zollinger-Ellison Syndrome and non-beta islet cell tumors and determine the effectiveness of combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin.
Interventions
- DRUG combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 999 participants |
| Start Date | 1978-09 |
| Est. Completion | 2003-08 |
| Phase | Phase 2 |
What the finished NCT00001165 record still lists
NCT00001165 is an interventional study that assigns participants to a tested intervention. The registered 999 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (651% higher).
The record links to 0 conditions, and to 1 intervention - of which combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin is the first listed.
NCT00001165 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00001165 about?
NCT00001165 is a clinical study titled "Combination Chemotherapy in Patients With Zollinger-Ellison Syndrome and Tumors of the Pancreas". Patients with Zollinger-Ellison Syndrome suffer from ulcers of the upper gastrointestinal tract, higher than normal levels of gastric acid, and tumors of the pancreas known as non-beta islet cell tumors. Prior to the use of drugs to cure the ulcers, patients typically died due to severe ulcers. Bec...
What is the current status of trial NCT00001165?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 999 participants. The study started on 1978-09. Estimated completion is 2003-08.
What interventions are being tested in trial NCT00001165?
The interventions under investigation include: combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin (DRUG).
Who is sponsoring clinical trial NCT00001165?
This trial is sponsored by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), which has 490 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00001165's enrollment target sits among peer trials
999 26th of 2000 higher than 1,975 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02986048 · 999 participants
Proton Therapy Patient Registry
- NCT04703244 · 999 participants
Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
- NCT01036581 · 1,000 participants · NA
Advanced Functional and Structural MRI Techniques for Neuropharmacological Imaging
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia